Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 92.0 Cr.
- Current Price ₹ 172
- High / Low ₹ 310 / 153
- Stock P/E 11.5
- Book Value ₹ 66.2
- Dividend Yield 0.00 %
- ROCE 35.2 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 136 days to 85.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 17.80 | 61.73 | 83.19 | |
| 15.54 | 52.85 | 71.70 | |
| Operating Profit | 2.26 | 8.88 | 11.49 |
| OPM % | 12.70% | 14.39% | 13.81% |
| 0.03 | 0.08 | 0.08 | |
| Interest | 0.09 | 0.21 | 0.55 |
| Depreciation | 0.01 | 0.02 | 0.03 |
| Profit before tax | 2.19 | 8.73 | 10.99 |
| Tax % | 27.85% | 27.49% | |
| 1.59 | 6.33 | 8.02 | |
| EPS in Rs | 3.24 | 12.74 | 15.56 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 152% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 |
| Reserves | 13.32 | 22.77 | 30.04 |
| 1.60 | 3.26 | 6.87 | |
| 0.96 | 4.57 | 9.25 | |
| Total Liabilities | 20.78 | 35.57 | 51.51 |
| 0.05 | 1.65 | 1.73 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.42 | 0.43 | 0.43 |
| 20.31 | 33.49 | 49.35 | |
| Total Assets | 20.78 | 35.57 | 51.51 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.87 | 1.21 | |
| -0.52 | -1.56 | |
| 13.13 | 2.86 | |
| Net Cash Flow | 8.74 | 2.50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 66.03 | 86.09 |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 66.03 | 86.09 |
| Working Capital Days | 186.81 | 85.56 |
| ROCE % | 35.18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
1d - Ms. Ragini Maurya resigned as Company Secretary & Compliance Officer effective 28-Feb-2026.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
24 Feb - First counter of Stergic Pharmacy (subsidiary) became operational 23 Feb 2026 at Deep Vihar, Rohini Sector-22, Delhi.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Property Taken On Lease.
28 Jan - New warehouse leased at Nathupur, Sonipat from 01.02.2026 to 31.01.2031 (five-year lease).
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Jan - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for your reference.
-
Announcement under Regulation 30 (LODR)-Allotment
17 Dec 2025 - Allotment of 392,000 preferential warrants at Rs.251 each (Rs98,392,000) on 17-Dec-2025; 25% paid; convertible within 18 months.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.